NCT06221462
Not yet recruiting
Phase 2
Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY): a Prospective Single Center, Open Label, Phase II Study
Ningbo No.2 Hospital0 sites30 target enrollmentStarted: February 1, 2024Last updated:
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Ningbo No.2 Hospital
- Enrollment
- 30
- Primary Endpoint
- major pathological response (MPR)
Overview
Brief Summary
This is a prospective single-center, open-label, phase II study evaluating the efficacy of sintilimab plus anlotinib as a neoadjuvant regimen in the treatment of IB-IIIB resectable non-small cell lung cancer.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Providing written informed consent prior to initiating the study.
- •Regardless of sex, aged ≥18 years and ≤75 years.
- •Histologically confirmed NSCLC.
- •At least one radiologically measureable lesion according to response evaluation criteria in solid tumors version 1.1(RECIST V1.1).
- •Treatment-naïve IB-IIIB resectable NSCLC (American Joint Committee on Cancer 8th tumor-node-metastasis classification).
- •Epidermal growth factor receptor(EFGR)/anaplastic lymphoma kinase(ALK)/ROS proto-oncogene 1(ROS1) wild type NSCLC.
- •Absence of bleeding risk.
- •Consent to surgical treatment.
- •Indication for surgery confirmed by surgeons.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
Exclusion Criteria
- •Exclusion criteria as follows：
- •Other malignancy rather than NSCLC diagnosed within 5 years prior to the first dose of the study given, except for definitively treated basal cell carcinoma, squamous cell carcinoma of the skin, and/or in situ carcinoma.
- •Enrolled in an ongoing interventional clinical trial, or receiving other study drugs or study medical devices within 4 weeks prior to the first dose of this study drugs.
- •A history of receiving the following therapies: anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death ligand-1 (anti-PD-L1) or anti-programmed cell death ligand-2 (anti-PD-L2) drugs, or drugs targeting T cell receptor (such as cytotoxic T-lymphocyte-associated protein 4, tumor necrosis factor receptor superfamily member 4 and CD137).
- •A history of receiving targeted therapy such as anti-vascular endothelial growth receptor (VEGR)/ vascular endothelial growth factor receptor (VEGFR), rapidly accelerated fibrosarcoma(RAF), mitogen-activated protein kinase(MAPK), platelet-derived growth factor Receptor(PDGFR) or fibroblast growth factor receptor(FGFR).
- •Receiving traditional Chinese medication or immunomodulatory drugs (including thymopentin, interferon, interleukin, except for controlling pleural effusion) as systemic therapy within 2 weeks prior to the first dose of the study drugs.
- •Active systemic auto-immune disease requiring systemic treatment within 2 years prior to the first dose of the study drugs, such as the use of disease-modifying drugs, glucocorticoids or immunosuppressants. Alternative therapies (such as thyroid hormone, insulin, or physiological glucocorticoids used for adrenal or pituitary insufficiency) are not considered as systemic treatment.
- •Systemic glucocorticoid therapy (excluding nasal, inhaled or other local routes of glucocorticoids) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugs.
- •Undergoing allogeneic organ transplant (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplant.
- •Allergy to the active ingredient or excipients of the study drug, sintilimab.
Arms & Interventions
treatment arm
Experimental
Intervention: Sintilimab (Drug)
treatment arm
Experimental
Intervention: Anlotinib (Drug)
Outcomes
Primary Outcomes
major pathological response (MPR)
Time Frame: 10 days postoperatively
Viable tumor cells are no more than 10% in the resected specimen
Secondary Outcomes
- treatment-related adverse events (TRAEs)(90 days after the last dose of study drugs)
- rate of operative complications(30 days postoperatively)
- pathological complete response (pCR)(10 days postoperatively)
- disease-free survival (DFS)(5 years)
- overall survival(OS)(5 years)
Investigators
Similar Trials
Recruiting
Phase 2
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)Esophageal Squamous Cell Carcinoma (ESCC)NCT06709417Shanghai Chest Hospital52
Active, not recruiting
Phase 2
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBCTriple Negative Breast CancerNCT04877821Guangdong Provincial People's Hospital31
Recruiting
Phase 2
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural MesotheliomaMesothelioma, MalignantMesothelioma, Malignant PleuralMesothelioma Malignant AdvancedNCT05188859Cancer Institute and Hospital, Chinese Academy of Medical Sciences29
Unknown
Phase 2
Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLCMetastatic NSCLCRecurrent NSCLCAdvanced Non-Small Cell Squamous Lung CancerNCT04846452The First Affiliated Hospital with Nanjing Medical University40
Unknown
Phase 2
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）Non-small Cell Lung CancerNCT04459611Second Affiliated Hospital, School of Medicine, Zhejiang University60